The stock of Spark Therapeutics Inc (NASDAQ:ONCE) is a huge mover today! About 240,645 shares traded hands. Spark Therapeutics Inc (NASDAQ:ONCE) has risen 58.01% since April 18, 2016 and is uptrending. It has outperformed by 53.58% the S&P500.
The move comes after 5 months negative chart setup for the $1.57 billion company. It was reported on Nov, 18 by Barchart.com. We have $52.54 PT which if reached, will make NASDAQ:ONCE worth $78.50 million less.
Spark Therapeutics Inc (NASDAQ:ONCE) Ratings Coverage
Out of 10 analysts covering Spark Therapeutics (NASDAQ:ONCE), 5 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 50% are positive. Spark Therapeutics has been the topic of 12 analyst reports since August 21, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Evercore on Tuesday, April 12. Roth Capital maintained the shares of ONCE in a report on Monday, October 5 with “Buy” rating. On Thursday, December 24 the stock rating was downgraded by Wunderlich to “Hold”. The stock has “Sell” rating given by Zacks on Wednesday, September 2. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. Zacks downgraded the shares of ONCE in a report on Friday, August 21 to “Hold” rating. The firm has “Hold” rating given on Thursday, June 2 by Jefferies. The firm has “Neutral” rating given on Wednesday, December 23 by Chardan Capital Markets. The company was initiated on Friday, September 2 by Stifel Nicolaus. The stock has “Buy” rating given by Cantor Fitzgerald on Thursday, June 23.
According to Zacks Investment Research, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 1.79 in Q2 2016. Its down 0.32, from 2.11 in 2016Q1. The ratio dropped, as 18 funds sold all Spark Therapeutics Inc shares owned while 18 reduced positions. 28 funds bought stakes while 48 increased positions. They now own 23.88 million shares or 24.93% more from 19.12 million shares in 2016Q1.
Federated Pa holds 1.65M shares or 0.25% of its portfolio. Architects owns 170 shares or 0% of their US portfolio. Moreover, Price T Rowe Associate Md has 0.03% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 2.66 million shares. Axa holds 140,278 shares or 0.03% of its portfolio. Great West Life Assurance Co Can has invested 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE). Deerfield Management holds 0.74% or 368,000 shares in its portfolio. Teachers owns 27,324 shares or 0% of their US portfolio. The Massachusetts-based Eventide Asset Mgmt Ltd Liability Corp has invested 0.47% in Spark Therapeutics Inc (NASDAQ:ONCE). The New York-based Millennium Limited Company has invested 0.04% in Spark Therapeutics Inc (NASDAQ:ONCE). Hanseatic Services Incorporated holds 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE) for 35 shares. Rs Invest Mgmt Communication Ltd Liability Corporation owns 439,094 shares or 0.23% of their US portfolio. Massachusetts Fin Ma has 112,402 shares for 0% of their US portfolio. Emerald Mutual Fund Advisers owns 49,916 shares or 0.14% of their US portfolio. Principal Financial Gru last reported 19,520 shares in the company. Rock Springs Capital Mgmt L P, a Maryland-based fund reported 610,000 shares.
More important recent Spark Therapeutics Inc (NASDAQ:ONCE) news were published by: Fool.com which released: “Spark Therapeutics Inc. Tumbled as Much as 25% on Thursday — Here’s Why” on November 03, 2016, also Seekingalpha.com published article titled: “Spark Therapeutics, Inc.’s (ONCE) CEO Jeffrey Marrazzo on Q3 2016 Results …”, Philly.com published: “Spark Therapeutics releases gene-therapy data” on August 10, 2016. More interesting news about Spark Therapeutics Inc (NASDAQ:ONCE) was released by: Fool.com and their article: “Why Spark Therapeutics Caught Fire and Rallied Higher Today” with publication date: May 19, 2016.
ONCE Company Profile
Spark Therapeutics, Inc. (Spark), incorporated on March 13, 2013, is engaged in developing products in the field of gene therapy. The Firm focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. The Company’s SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). The Company’s product candidates include SPK-CHM and SPK-FIX. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. The Firm is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.